Cardio-oncology-beyond anthracyclines and ejection fraction

Paul D. Geenty; Ann T. Gregory; Mark Nolan; A. Robert Denniss; Salvatore Pepe; Aaron L. Sverdlov; Liza Thomas

doi:10.1016/j.hlc.2024.05.002

Cardio-oncology-beyond anthracyclines and ejection fraction

Paul D. Geenty, Ann T. Gregory, Mark Nolan, A. Robert Denniss, Salvatore Pepe, Aaron L. Sverdlov, Liza Thomas

School of Medicine

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Cancer is the second leading cause of death worldwide [1]; however, survival has steadily improved with early diagnosis and the development of new therapies. As a result, an increasingly large number of cancer survivors are exposed to the long-term chronic effects of both cancer and cancer therapies.

Original language	English
Pages (from-to)	547-552
Number of pages	6
Journal	Heart, Lung and Circulation
Volume	33
Issue number	5
DOIs	https://doi.org/10.1016/j.hlc.2024.05.002
Publication status	Published - May 2024

Keywords

Cardio-Oncology
Cardiology
Cardiovascular disease
Cardiovascular toxicity
Oncology
Risk management

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.hlc.2024.05.002

Cite this

@article{ab9f0d6f3904401e8d8030d3bda7a136,

title = "Cardio-oncology-beyond anthracyclines and ejection fraction",

abstract = "Cancer is the second leading cause of death worldwide [1]; however, survival has steadily improved with early diagnosis and the development of new therapies. As a result, an increasingly large number of cancer survivors are exposed to the long-term chronic effects of both cancer and cancer therapies.",

keywords = "Cardio-Oncology, Cardiology, Cardiovascular disease, Cardiovascular toxicity, Oncology, Risk management",

author = "Geenty, {Paul D.} and Gregory, {Ann T.} and Mark Nolan and Denniss, {A. Robert} and Salvatore Pepe and Sverdlov, {Aaron L.} and Liza Thomas",

year = "2024",

month = may,

doi = "10.1016/j.hlc.2024.05.002",

language = "English",

volume = "33",

pages = "547--552",

journal = "Heart, Lung and Circulation",

issn = "1443-9506",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - Cardio-oncology-beyond anthracyclines and ejection fraction

AU - Geenty, Paul D.

AU - Gregory, Ann T.

AU - Nolan, Mark

AU - Denniss, A. Robert

AU - Pepe, Salvatore

AU - Sverdlov, Aaron L.

AU - Thomas, Liza

PY - 2024/5

Y1 - 2024/5

N2 - Cancer is the second leading cause of death worldwide [1]; however, survival has steadily improved with early diagnosis and the development of new therapies. As a result, an increasingly large number of cancer survivors are exposed to the long-term chronic effects of both cancer and cancer therapies.

AB - Cancer is the second leading cause of death worldwide [1]; however, survival has steadily improved with early diagnosis and the development of new therapies. As a result, an increasingly large number of cancer survivors are exposed to the long-term chronic effects of both cancer and cancer therapies.

KW - Cardio-Oncology

KW - Cardiology

KW - Cardiovascular disease

KW - Cardiovascular toxicity

KW - Oncology

KW - Risk management

UR - http://www.scopus.com/inward/record.url?scp=85194467172&partnerID=8YFLogxK

UR - https://go.openathens.net/redirector/westernsydney.edu.au?url=https://doi.org/10.1016/j.hlc.2024.05.002

U2 - 10.1016/j.hlc.2024.05.002

DO - 10.1016/j.hlc.2024.05.002

M3 - Article

C2 - 38823894

AN - SCOPUS:85194467172

SN - 1443-9506

VL - 33

SP - 547

EP - 552

JO - Heart, Lung and Circulation

JF - Heart, Lung and Circulation

IS - 5

ER -

Cardio-oncology-beyond anthracyclines and ejection fraction

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this